Immutep To Present Late-Breaking Abstract In Head & Neck Cancer At ESMO Congress 2024
Portfolio Pulse from Benzinga Newsdesk
Immutep Limited will present a late-breaking abstract at the ESMO Congress 2024, detailing results from its TACTI-003 Phase IIb trial in head & neck cancer.
August 20, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep Limited will present significant trial results at the ESMO Congress 2024, which could impact its stock price positively.
The presentation of late-breaking trial results at a major oncology conference like ESMO can generate positive attention and investor interest, potentially boosting the stock price of Immutep.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100